Cooperative Agreement NU01DD000005

The U.S. Centers for Disease Control and Prevention (CDC) awarded a $286,510 Cooperative Agreement under the Blood Disorder Program: Prevention, Surveillance, and Research (CFDA 93.080) to the Center for Public Health Innovation, a woman-owned non-profit organization, for the Sickle Cell Data Collection Program - 2023. This 5-year project, beginning on September 30, 2023, aims to work with state health agencies and other partners to plan, develop, implement, coordinate, and evaluate programs and...

Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded The Ohio State University a $765,931 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) on August 22, 2025, to support a multi-center hybrid effectiveness-implementation trial titled "Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults with Sickle Cell Disease (PF-GUIDE)." The grant funds the development and evaluation of patient-centered, evidence-based...

Federal Grant Award Summary Award Details: The National Heart, Lung, and Blood Institute (NHLBI) awarded Emory University a Project Grant totaling $646,383 under the Cardiovascular Diseases Research program (CFDA 93.837). The award was obligated on September 15, 2025, with an ultimate completion date of June 30, 2030. Research Scope and Deliverables: This project investigates red blood cell (RBC) transfusion survival and effectiveness in recipients with sickle cell disease (SCD), a clinical...

The University of North Carolina at Chapel Hill received a $171,488 Project Grant award from the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 30, 2025, with completion targeted for August 31, 2026. This research project will deliver a nationwide examination of access to comprehensive care in sickle cell disease (SCD), a complex inherited blood disorder affecting at least 100,000 Americans and associated with a...

Federal Grant Award Summary The National Heart, Lung, and Blood Institute (NHLBI) awarded New York Blood Center, Inc. a Project Grant of $1,587,223 (effective August 1, 2025 through April 30, 2029) under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct basic research on erythroblastic island macrophages in normal and disordered erythropoiesis. The funded research will investigate the mechanisms by which erythroblastic island macrophages support normal red blood cell...

Grant Award Summary Emory University was awarded $797,648 in Project Grant funding from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective June 1, 2026, through February 28, 2031. The grant supports research investigating red blood cell (RBC)-bound cell-free DNA (cfDNA) as a predictor of acute anemia in sickle cell disease (SCD). The research will generate scientific knowledge regarding the mechanisms driving acute...

Federal Project Grant Award Summary Emory University received a $391,211 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective June 1, 2026, through May 31, 2029. The award funds research investigating alloimmune responses to hemophilia therapeutics, specifically examining the mechanisms underlying anti-drug antibody development against coagulation factor proteins. The research addresses a critical...

Federal Grant Award Summary Optimizing HCT Outcomes: A Multi-Omic Investigation The National Heart, Lung, and Blood Institute (NHLBI) awarded Boston Children's Hospital $5.96 million under the Cardiovascular Diseases Research program (CFDA 93.837) on August 15, 2025, for a five-year project extending through May 31, 2030. This Project Grant supports a multi-omic investigation designed to optimize outcomes for hematopoietic stem cell transplantation (HCT), a critical treatment for high-risk...

Federal Project Grant Award Summary The University of Pittsburgh received a $190,188 Project Grant from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), awarded April 10, 2026, with completion targeted for March 31, 2031. The project, "Biomarkers and Predictors of Treatment Response in Chronic Anemia in Sickle Cell Disease," will deliver research identifying biomarkers and predictive factors to guide...

Federal Project Grant Award Summary Vitalant Research Institute received a $262,500 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), effective September 15, 2025, with completion targeted for August 31, 2027. The award funds research aimed at defining the drivers of mitochondrial DNA (mtDNA) levels in blood components and investigating their impact on transfusion-related acute lung injury (TRALI). The...